Tevogen Bio Publishes Phase I Clinical Trial Data For TVGN 489 In Blood Advances; Investigational Allogeneic SARS-CoV-2 Specific Cytotoxic CD8+ T Cell Therapy; Company Focused On Developing T Cell Therapeutics In Oncology, Neurology, And Virology
$TVGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- Interventional arm patients, totaling twelve high-risk individuals, 50% of whom were immunocompromised, and 40% of whom were immunocompromised due to preexisting cancers, received a single infusion of one of four escalating doses of TVGN 489, a product containing 68.5% SARS-CoV-2-specific CD8+ CTLs/total cells.
- Symptom improvement and resolution in treatment arm patients were compared to an observational group of eighteen patients who received standard care, making a total of 30 study participants.
- TVGN 489 was well-tolerated at all four doses tested.
- Nasal swab PCR data showed 88% or greater viral elimination in 92% of patients by day +4 and > 99% viral elimination in all patients by day +14.
- No progression of disease or the development of Long COVID was observed in the treatment group, despite the prevalence of immunocompromised patients.
- TVGN 489 did not interfere with the development of endogenous anti-SARS-CoV-2 humoral or cellular responses.
- T-cell receptor beta (TCRβ) analysis comparing TVGN 489 responses derived from the CTL donor versus recipients showed persistence of donor-derived CTLs through the end of the 6-month follow-up period.